Viatris (VTRS) Total Non-Current Liabilities (2019 - 2026)

Viatris' (VTRS) quarterly Total Non-Current Liabilities came in at $20.1 billion in Q1 2026, down 4.22% year-on-year from $21.0 billion in Q1 2025, and down 1.82% quarter-over-quarter from $20.5 billion in Q4 2025.

Viatris (VTRS) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends

Viatris' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $20.1 billion for Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities fell 4.22% year-over-year to $20.1 billion in Q1 2026; TTM through Mar 2026 was $20.1 billion, a 4.22% decrease from a year earlier, with the FY2025 full-year figure at $20.5 billion, down 2.19% from the prior year.
  • Total Non-Current Liabilities fell to $20.1 billion in Q1 2026 per VTRS's latest filing, from $20.5 billion in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $31.1 billion in Q1 2022 and bottomed at $20.1 billion in Q1 2026.
  • The 5-year median for Total Non-Current Liabilities is $25.7 billion (2023), against an average of $24.7 billion.
  • Across the five-year window, Total Non-Current Liabilities grew 1.28% in 2024 and fell 22.25% in 2025, its largest moves.
  • Year by year, Total Non-Current Liabilities stood at $27.2 billion in 2022, then declined by 5.49% to $25.7 billion in 2023, then fell by 18.58% to $20.9 billion in 2024, then retreated by 2.19% to $20.5 billion in 2025, then retreated by 1.82% to $20.1 billion in 2026.
  • Per Business Quant, the three latest VTRS Total Non-Current Liabilities figures stand at $20.1 billion (Q1 2026), $20.5 billion (Q4 2025), and $20.9 billion (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Haleon 88.07 Bn 86.20 Bn - 14.92 Bn
2 Teva Pharmaceutical Industries 35.75 Bn 32.01 Bn 1.97 Bn 18.28 Bn
3 Zoetis 31.84 Bn 29.90 Bn 1.62 Bn 11.64 Bn
4 Takeda Pharmaceutical 27.18 Bn 23.12 Bn 4.39 Bn 33.47 Bn
5 United Therapeutics 23.09 Bn 20.93 Bn 648.10 Mn 599.10 Mn
6 RedHill Biopharma 21.32 Bn 21.32 Bn - 1.86 Mn
7 Viatris 19.96 Bn 18.16 Bn 1.16 Bn 20.09 Bn
8 Neurocrine Biosciences 17.66 Bn 16.34 Bn 800.70 Mn 1.24 Bn
9 Elanco Animal Health 12.44 Bn 12.02 Bn 785.00 Mn 6.26 Bn
10 Vireo Growth 10.53 Bn 10.38 Bn 59.30 Mn 604.70 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 20.09 Bn
Dec 31, 2025 20.47 Bn
Sep 30, 2025 20.88 Bn
Jun 30, 2025 21.01 Bn
Mar 31, 2025 20.98 Bn
Dec 31, 2024 20.93 Bn
Sep 30, 2024 23.09 Bn
Jun 30, 2024 25.47 Bn
Mar 31, 2024 26.98 Bn
Dec 31, 2023 25.70 Bn
Sep 30, 2023 26.23 Bn
Jun 30, 2023 26.18 Bn
Mar 31, 2023 26.64 Bn
Dec 31, 2022 27.19 Bn
Sep 30, 2022 27.74 Bn
Jun 30, 2022 29.51 Bn
Mar 31, 2022 31.13 Bn
Sep 30, 2021 32.88 Bn
Jun 30, 2021 34.54 Bn
Mar 31, 2021 35.09 Bn